Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

QUOTED. 26 July 2019. Michael Mahoney.

Executive Summary

Boston Scientific beat Wall Street's second-quarter profit expectations, but fell shy of analysts' predictions on revenue. See what Boston Scientific's CEO Michael Mahoney said about it here.

“The combined strength of Watchman, Acurate, Lotus Edge and Sentinel position us well to deliver on our guidance for $700m to $725m in structural heart revenue in 2019.” – Michael Mahoney, CEO, Boston Scientific

Click here for a free trial of Medtech Insight

Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

MT125418

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel